Last reviewed · How we verify
ALECSAT cell based immunotherapy
Cell-based immunotherapy targeting cancer cells
Cell-based immunotherapy targeting cancer cells Used for Treatment of cancer.
At a glance
| Generic name | ALECSAT cell based immunotherapy |
|---|---|
| Sponsor | CytoVac A/S |
| Drug class | Immunotherapy |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
This involves using a patient's own immune cells to recognize and attack cancer cells.
Approved indications
- Treatment of cancer
Common side effects
Key clinical trials
- A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients (PHASE1)
- Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan (PHASE2)
- Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy (PHASE1)
- Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALECSAT cell based immunotherapy CI brief — competitive landscape report
- ALECSAT cell based immunotherapy updates RSS · CI watch RSS
- CytoVac A/S portfolio CI